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ABSTRACT
The stimulation of the immune system using oncolytic adenoviruses (OAds) has attracted significant
interest and several studies suggested that OAds immunogenicity might be important for their efficacy.
Therefore, we developed a versatile and rapid system to adsorb tumor-specific major histocompatibility
complex class I (MHC-I) peptides onto the viral surface to drive the immune response toward the tumor
epitopes. By studying the model epitope SIINFEKL, we demonstrated that the peptide-coated OAd
(PeptiCRAd) retains its infectivity and the cross presentation of the modified-exogenous epitope on MHC-I
is not hindered. We then showed that the SIINFEKL-targeting PeptiCRAd achieves a superior antitumor
efficacy and increases the percentage of antitumor CD8C T cells and mature epitope-specific dendritic
cells in vivo. PeptiCRAds loaded with clinically relevant tumor epitopes derived from tyrosinase-related
protein 2 (TRP-2) and human gp100 could reduce the growth of primary-treated tumors and secondary-
untreated melanomas, promoting the expansion of antigen-specific T-cell populations. Finally, we tested
PeptiCRAd in humanized mice bearing human melanomas. In this model, a PeptiCRAd targeting the
human melanoma-associated antigen A1 (MAGE-A1) and expressing granulocyte and macrophage colony-
stimulating factor (GM-CSF) was able to eradicate established tumors and increased the human MAGE-A1-
specific CD8C T cell population. Herein, we show that the immunogenicity of OAds plays a key role in their
efficacy and it can be exploited to direct the immune response system toward exogenous tumor epitopes.
This versatile and rapid system overcomes the immunodominance of the virus and elicits a tumor-specific








OAds selectively kill tumor cells 1,2 countering tumor
growth and favoring the spreading of damage-associated
molecular patterns (DAMPs) that can, under certain
circumstances, lead to the activation of surrounding
antigen-presenting cells (APCs) 3,4 and some degrees of
expansion of tumor-specific T-lymphocytes.5 However, the
lack of sufficient number of tumor-specific T cells and
immunosuppressive mechanisms limits the efficacy of
OAds.6 More sophisticated oncolytic vectors encode for
immune-modulating molecules such as IL-23,7 TNFa,8
CD40L,9,10 or GM-CSF.5,11,12 In addition, to further
improve the specificity of the immune response, adenovi-
ruses encoding for tumor antigens have been designed.13
The efficacy of these oncolytic agents, however, depends on
their persistence into the patients and their transduction
efficiency, which is a common limitation for all adenoviral
vectors used in clinical trials due to pre-existing immunity
14 and the rapid production of neutralizing antibodies.15 In
addition, the time required for the genetic manipulation of
the different viruses encoding for different antigens and the
consequent re-evaluation by the competent authorities
(FDA and/or EMEA) makes this approach incompatible
with next generation of personalized approaches that rely
on the identification of patient-specific antigenic signatures
to adapt immunotherapeutic protocols.
To this end, we specifically developed a novel oncolytic
vaccine platform in which tumor peptides are not expressed by
the virus and are not part of the viral proteins, in contrast to
the vast majority of current approaches. The peptides are
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instead adsorbed onto the viral capsid, allowing for the efficient
co-delivery of adjuvant (virus) and tumor-specific epitopes
(Fig. 1). Thus, the oncolytic virus acts as an “active” carrier that
is able to kill tumor cells and to boost the immunological
response against the chosen antigen. This method does not
involve chemical or genetic modification of the virus, signifi-
cantly increasing the rapidity and the versatility of the prepara-
tion. As a direct consequence, this system addresses the need
for tumor-specific and even personalized therapies that could
account for the expression of different antigens in different
patients or different antigens in different stages of the same
tumor.
In this study, we characterized the physical and biological
properties of Peptide-coated Conditionally Replicating Adeno-
viruses (PeptiCRAds). We demonstrated that by absorbing
tumor-specific MHC-I-restricted peptides onto the viral capsid,
we can direct the immunity toward the tumor, leading to a
significantly increased efficacy in different models of murine
melanoma and human melanoma in humanized mice. Pepti-
CRAd represents a novel oncolytic vaccine platform that is able
to fully exploit the immunogenicity of OAds and that can be
rapidly adapted to different antigens and tumors without any
genetic modification.
Results
The negative charge of the adenovirus capsid can be used
to complex positively charged immunogenic peptides,
forming PeptiCRAd
Adenovirus capsids is negatively charged 16 bearing mostly
acidic/negative regions in the hexon protein (red and pale red
regions in Fig. S1), thus we hypothesized that MHC-I-restricted
peptides, modified to become positively charged, would bind to
the capsid of the virus via electrostatic interactions. We tested
our hypothesis by using the MHC-I epitope SIINFEKL derived
from chicken ovalbumin (OVA).17 The addition of a poly-
lysine (polyK) chain to the aminoacidic sequence increases the
net charge of the peptide from 0 to C6 mV at neutral pH
(Fig. 2A). Next, we coated APTES silica SiO2 sensor with OAds
(Fig. S2A) and we injected increasing concentrations of SIIN-
FEKL or polyK-SIINFEKL into the surface plasmon resonance
(SPR) system (Fig. 2B). No virus-peptide interaction was
observed with the unmodified neutral SIINFEKL (Fig. 2B,
dashed line), whereas a concentration-dependent interaction
was observed with the modified positive polyK-SIINFEKL
(Fig. 2B, solid line). In these experimental settings, we observed
a plateau when using solutions of peptide with a concentration
above 7 uM. We found that the binding model for these
Figure 1. Schematic of PeptiCRAd (Peptide-coated Conditionally Replicating Ade-
novirus). PeptiCRAd is a novel cancer vaccine platform that exploits the natural
immunogenicity of adenoviruses. OAds act as adjuvants for exogenous MHC-I
tumor epitopes that are loaded onto the viral capsid by electrostatic interactions.
These peptides could be known MHC-I epitopes or patient-derived tumor epitopes.
Therefore, PeptiCRAd retains all the properties of a conventional oncolytic adeno-
virus (direct tumor-killing ability and possibility to express immune-stimulating
molecules), however, it has a superior ability to stimulate a tumor-specific immune
response.
Figure 2. Physical characterization of the interaction between the modified MHC-I epitope SIINFEKL and OAd. (A) The net charge of SIINFEKL (dashed gray line, circles) or
polyK-SIINFEKL (black line, triangles) is shown as a function of pH. (B) SPR was used to study the interaction between Ad5D24 oncolytic virus and increasing concentra-
tions (0.15, 0.3, 0.6, 1.2, 2.4, 7.2, and 21.6 mM) of either SIINFEKL (dashed line) or polyK-SIINFEKL (solid line). (C) zeta potential (dashed gray line, left axis) and hydrody-
namic diameter (solid black line, right axis) of virus-peptide complexes. Time-dependent study of complexs zeta potential (D) and hydrodynamic diameter (E) after
incubation at room temperature. Representative results from two different experiments are shown. The data are plotted as the mean § SD (n D 3).


































electrostatic interactions is a complex one, since high goodness
of fit (R2D0,997) is observed only when applying a co-operativ-
ity model to the data (Fig. S2B). In addition, according to this
model, we were able to estimate a binding constant of
2.88 £ 10¡6 M and a Hill coefficient of C2.68 indicating a
positive co-operativity.
Next, we studied how the amount of peptide in the coating
reaction could affect the OAds-peptide complexes (Fig. 2C).
The lowest OAds: peptide ratio (1:5) was able to increase the
charge of the viral particles from ¡29.7 § 0.5 to C6.3 §
0.06 mV, although under these conditions, heavy aggregation
was observed, as indicated by an increase in the size of the com-
plexes (800 § 13.5 nm). Above 1:5, the net charge reached a
plateau-like kinetic as we measured zeta potentials of C17.5 §
0.2, C18.4 § 0.1 and C18 § 0.8 mV for the 1:50, 1:100 and
1:500 ratios, respectively. However, only at a ratio of 1:500 the
hydrodynamic diameter of the complex decreased (reaching
~120 nm), which represents the normal diameter of adenoviral
particles. The complex presented good stability and no signifi-
cant decrease of zeta potential occurred 30 and 45 min after
incubation in the same conditions (Fig. 2D) compared to
15 min incubation. In addition, we report no aggregation at
these time points (Fig. 2E) but only an increase in the hydrody-
namic diameter which can be caused by the increased presence
of water molecules on the particle. To prove that interaction is
not restricted to polyK-SIINFEKL peptide, we complexed the
adenovirus with another modified peptide, the polyK-MAGE
A1 epitope. We observed an increase of the zeta potential
(Fig. S2C) compared to the naked adenovirus and no aggrega-
tion (Fig. S2D) of the particles.
Modified MHC-I epitopes adsorbed onto peptiCRAd are
efficiently cross presented
Next, we investigated whether the presence and the position of
the polyK chain could affect the efficiency of cross presentation
of the epitope on MHC-I. We pulsed ex vivo-cultured spleeno-
cytes (from C57BL/6 mice) with two different lysine-extended
versions: polyK-SIINFEKL (N-terminus extended) and SIIN-
FEKL-polyK (C-terminus extended). As a negative control, we
included extended SIINFEKL containing an amino caproic
(AHX) residue, which is a well-known analog of lysine that can
inhibit the proteolytic activity of the proteasome. We then
assessed the cross presentation of the mature form of the epi-
tope (SIINFEKL) on MHC-I by flow cytometry.18
The 94.5% of the spleenocytes pulsed with the N-terminus-
extended peptide cross-presented SIINFEKL. In contrast, when
the spleenocytes were pulsed with the C-terminus-extended
SIINFEKL-polyK, the stained population decreased to 27.1%
(Fig. 3A). Based on these findings, we chose the N-terminus-
extended version (polyK-SIINFEKL) for further studies.
Next, we investigated if the adsorption of the modified SIIN-
FEKL onto the viral capsid could affect its cross presentation.
As in the previous experiment, we incubated mouse spleeno-
cytes with the polyK-SIINFEKL or with OVA-PeptiCRAd (i.e.
OAd coated with polyK-SIINFEKL). We found that all the con-
ditions allowed for efficient MHC-I-restricted presentation of
the SIINFEKL peptide (Fig. 3B).
PeptiCRAd shows increased infectivity compared with
unmodified viruses
We investigated whether coating the viruses with modified pep-
tides would affect their biological properties. We chose to study
a human colorectal adenocarcinoma cell line (CACO-2)
expressing low levels of coxsackie and adenovirus receptor
(CAR) a human melanoma cell line expressing intermediate
levels of CAR (A2058) and another human melanoma cell line
expressing high levels of CAR (SK-MEL-2). PeptiCRAd showed
unaltered oncolytic activity compared to naked Ad5D24 virus
(Fig. 4A) in all cell lines; in addition we observed no toxic effect
upon cell viability due to the modified polyK-SIINFEKL
peptide.
Next, we evaluated the infectivity of PeptiCRAd by immu-
nocytochemistry (ICC; Fig. 4B). Whereas, we did not observe
any significant difference in SK-MEL-2 cell line, when testing
Figure 3. Cross-presentation of modified SIINFEKL analogs on MHC-I adsorbed or not adsorbed onto the viral capsid. (A) C57BL/6 fresh spleenocytes were incubated with
SIINFEKL, the amino caproic acid-containing SIINFEKL-AHX-polyK, the C-terminus-extended SIINFEKL-polyK or the N-terminus-extended polyK-SIINFEKL. Cross presentation
was determined with APC anti-H-2Kb bound to SIINFEKL or isotype control antibodies. (B) Similar to (A), spleenocytes were infected with of OVA-PeptiCRAd, or incubated
with peptides SIINFEKL or polyK-SIINFEKL. The data are shown as the mean § SD (nD2). Significance was assessed using the unpaired students t-test;  p < 0.01,



































in vitro models with intermediate (A2058) and low (CACO-2)
levels of CAR, PeptiCRAd showed a significant increase
(p < 0.05) in infectivity compared with the naked adenovirus.
Characterization of the anti-tumor immunity and efficacy
of PeptiCRAd in a murine model of melanoma
To thoroughly study the antitumor efficacy of PeptiCRAd, we
first used a murine model of melanoma over-expressing
chicken OVA (B16-OVA).17 A pilot experiment was performed
using an OAd bearing the D24 deletion in E1A (Ad5D24) 2
coated with the modified poly-K-SIINFEKL. We observed a sig-
nificantly reduced tumor growth in mice treated with Pepti-
CRAd (Fig. S3). Therefore, we investigated further this model
by using a CpG-rich OAd (Ad5D24-CpG) 19 to further boost
immunity (Fig. 5) through Toll-like receptor 9 activation. The
study groups included mice treated with OVA-PeptiCRAd,
with non-complexed Ad5D24-CpG and SIINFEKL (Ad5D24-
CpGCSIINFEKL), with naked Ad5D24-CpG, with SIINFEKL
peptide alone or with saline solution (mock).
Intratumoral injections of PeptiCRAd significantly reduced
the tumor’s growth compared with treatment with saline
buffer, SIINFEKL peptide or the mixture of OAd and SIIN-
FEKL. At the end of the experiment, the average volume of the
tumors in the OVA-PeptiCRAd-treated mice was significantly
lower than in all other groups (Fig. 5A).
Next, we studied the immunological background, hypothe-
sizing that the increased antitumor efficacy could be explained
by a more efficient CD8C T cell response. To this end, we ana-
lyzed spleens (Fig. 5B), tumors (Fig. 5C) and draining lymph
nodes (Fig. 5D) of mice 7 and 16 d after the start of the treat-
ment (early and late time points respectively). At early time
point, the CD8C response against the SIINFEKL epitope was
generally low in spleens (Fig. 5B, left) and tumors (Fig. 5C,
left), with mice treated with SIINFEKL peptide alone showing
an increased trend. Mice treated with OVA-PeptiCRAd did not
show any increased SIINFEKL response in spleens and tumors
while we detected a larger population of epitope-specific CD8C
T cells in the draining lymph nodes (Fig. 5D, left) compared to
all other groups. At the end of the experiment (day 16), we
observed that mice treated with OVA-PeptiCRAd showed an
increased percentage of pentamer specific CD8C T cells in
spleens, tumors and lymph nodes (Figs. 5B, 5C and 5D on the
right).
Next, we studied the correlation between the immunological
response and the antitumor effect (Fig. 5E). We found that data
would fit best to a non-linear model. According to the expo-
nential model, a very good correlation between tumor volumes
and CD8C-response was found in spleens (R2C0.9995); in
tumors and lymph nodes the correlation was still high but
slightly lower than in spleens. Interestingly, in the correlation
analyses, the PeptiCRAd group consistently showed the small-
est tumor volume and the greatest immunological response.
Finally, we evaluated the effect of PeptiCRAd vaccination on
professional antigen presenting cells 7 and 16 d after the start
of the treatment (early and late time points respectively). In
particular, we were interested in the proportion of dendritic
cells (DCs; CD19¡ CD3¡ CD11cC) showing a mature pheno-
type (CD86high) and presenting the SIINFEKL peptide on
MHC-I. We hypothesized that these cells might be the ones
responsible for direct CD8C T cell activation through the cross-
presentation mechanism. At the late time point, mice treated
with PeptiCRAd showed a significantly higher percentage of
mature SIINFEKL-presenting DCs (p< 0.05) than mice treated
with the non-complexed Ad5D24-CpGCSIINFEKL (Fig. S4B).
When both time points are considered, PeptiCRAd induced the
biggest increase of CD86high OVAC DCs, 9.67-fold change
(Fig. 5F).
Multivalent PeptiCRAd shows enhanced antitumor activity
toward distant, untreated melanomas
Next, we studied the efficacy of PeptiCRAd upon non-treated
contralateral melanomas and whether targeting two tumor
Figure 4. PeptiCRAd retains intact oncolytic activity and displays increased infectivity in cell lines with low CAR expression. (A) cell viability assay in different cell lines. The
data are shown as the mean § SD (n D 3). (B) Infectivity assay by ICC. Cells have been infected with 10 vp/cell of either naked OAd or OVA-PeptiCRAd. The average num-
ber of spots per visual field is presented (5 non-overlapping visual fields have been acquired and used for the generation of the means). Representative data from two
independent experiments are shown as the mean § SD (n D 2). Significance was assessed using the unpaired t-test with Welch’s correction;  p < 0.05.


































Figure 5. Antitumor efficacy of PeptiCRAd and immunological analysis of antigen-specific CD8C T cells and DCs. C57BL/6 mice (nD8–9) received 3£105 B16-OVA cells in
both flanks. Treatment was initiated nine days later and included saline solution (mock), peptide alone (SIINFEKL), virus alone (Ad5D24-CpG), a mixture of virus and SIIN-
FEKL peptide (Ad5D24-CpGCSIINFEKL), and Ad5D24-polyK-SIINFEKL complex (OVA-PeptiCRAd). Mice were treated three times (on days 0, 2, and 7; black arrows). At day
7, before the third injection, mice from each group were sacrificed for early immunological analysis (nD 2–3). The late immunological analysis was performed on samples
collected at the end of the experiment (tumors and spleens n D 3–4; lymph nodes n D 2–3). (A) Average tumor volume is represented excluding mice sacrificed at day 7.
The percentage of SIINFEKL-PentamerC cells among CD19¡CD8C T-cells is reported for spleens (B), tumors (C) and draining lymph nodes (D) at early (left panels) and late
(right panels) time points. Samples from Ad5D24-CpG group were collected at day 12. Data are presented as the mean § SD. (E) The average tumor size at the end of
the experiment was plotted against the average percentage of SIINFEKL-PentamerC CD8C T cells at late time point. A correlation analysis was performed using a non-lin-
ear exponential model and the R square value is reported for each set of data. (E) Dendritic cells (CD19¡CD3¡CD11cC) showing a mature profile (CD86high) and cross-pre-
senting SIINFEKL on their H2-Kb was determined in the spleens 7 and 16 d after the start of the treatment. The fold change between the two time points is presented.



































antigens (via multivalent PeptiCRAd) would increase the over-
all efficacy. Therefore, we chose two polyK-modified versions
of the tumor-specific MHC-I-restricted epitopes SVYDFFVWL
(TRP-2180-188; restricted to the murine MHC-I molecule H-
2Kb) and KVPRNQDWL (human gp10025-33, or hgp100;
restricted to the murine MHC-I molecule H-2Db 20), both
expressed by B16-F10 cells.21
We first implanted 1£105 B16-F10 cells into the right
flank of C57BL/6 mice (Fig. 6A). After 10 days, intratu-
moral treatments were initiated as follows: (i) saline solu-
tion (mock), (ii) naked oncolytic virus (Ad5D24-CpG),
(iii) single-coated hgp100-PeptiCRAd, (iv) single-coated
TRP-2-PeptiCRAd, and (v) double-coated TRP-2-
hgp100-PeptiCRAd. Two days after the last treatment, we
injected 3£105 B16-F10 cells into the left flank of the
mice (Fig. 6A). The double-coated PeptiCRAd signifi-
cantly reduced the growth of the primary tumors com-
pared with the other control groups (Fig. 6B). When
analyzing the size of the secondary-untreated tumors, we
observed an increased efficacy of all three PeptiCRAds.
The overall growth of the secondary tumors was signifi-
cantly reduced by the double-coated PeptiCRAd
(Fig. S5). In particular, the secondary tumors of mice
treated with TRP-2-hgp100-PeptiCRAd were significantly
smaller compared with those in the controls receiving
saline solution (p < 0.01) or only Ad5D24-CpG (p <
0.05; Fig. 6C). Although not statistically significant, the
improved antitumor efficacy on the secondary melano-
mas was noticed also when comparing the double-tar-
geted PeptiCRAd to both the single-targeted ones.
To better clarify the mechanisms underpinning these results,
we performed a flow cytometry analysis to study the specific
CD8C T cell populations. In mice treated with TRP-2-hgp100
PeptiCRAd, we observed the largest cumulative relative
response of epitope-specific CD8C T cells in mice treated with
TRP-2-hgp100-PeptiCRAd (Fig. 6D).
Taken together, these results demonstrate that the Pepti-
CRAd approach is effective against a less immunogenic and
more aggressive melanoma model. In addition, targeting multi-
ple antigens might be important to increase the outcome of this
therapeutic protocol.
PeptiCRAd displays enhanced efficacy and antitumor
immunity in humanized mice bearing human tumors
Finally, we studied PeptiCRAd in a clinical-relevant model. To
this end, we first engrafted triple-knockout mice (NOD.Cg-
Prkdcscid-IL2rgtm1Wjl/SzJ, or NSG) with the human melanoma
cell line SK-MEL-2 and then HLA-A3 matched human periph-
eral blood mononuclear cells (PBMCs) from a healthy donor
were injected into the same mice intravenously. One day after,
mice were treated with PeptiCRAd, uncoated virus or saline
solution. We chose an epitope derived from MAGE-A196-104
(SLFRAVITK) and modified it to allow for interaction with the
viral capsid (polyK-SLFRAVITK). To maximize the stimulation
of the engrafted human immune system, we selected an OAd
expressing human GM-CSF.5
As expected, both viruses performed better than the control
mock, however, we found the MAGE-A1 PeptiCRAd to be sig-
nificantly more effective when compared to the uncoated virus
Figure 6. Targeting two tumor antigens with PeptiCRAd reduces the growth of both treated and untreated tumors. (A) C57BL/6 mice received 1£105 B16-F10 melanoma
cells on the right flank and 3£105 B16-F10 cells on their left flank two days after the last treatment. Only the right tumor was treated. (B) The growth of the primary
(right) tumor is presented as the mean § SD (n D 6–7). (C) The size of the secondary (left) tumors at the end of the experiment is reported for each individual mouse.
Tumor size oh hgp100-PeptiCRAd group is referred to day 11 before euthanasia of the group of mice. (D) The percentages of TRP-2- and hgp100-specific CD8C T cells in
spleens and inguinal lymph nodes form each mouse were normalized against mock, stacked into single columns and presented as the cumulative relative response for
each experimental group. Samples from hgp100-PeptiCRAd group were collected at day 11. Significance was assessed by using the unpaired Mann–Whitney test; p <
0.05; p < 0.01.


































(Fig. 7A). In fact, we observed a rapid rejection of the tumors in
mice treated with PeptiCRAd as shown by the area under the
curve for each group of mice (Fig. 7B). Interestingly, when the
same experiment was repeated in mice without a human
immune system, no clear difference was observed between Pep-
tiCRAd and the uncoated virus (Fig. 7C) suggesting the impor-
tant role of the immune system in the efficacy of our cancer
vaccine platform. To explore this hypothesis, we studied the
presence of human MAGE-A196-104-specific CD8
C T cells by
pentamer staining (Fig. 7D). We found the largest population
in the spleens of humanized mice treated with MAGE-A1
PeptiCRAd.
These data confirm our previous findings: PeptiCRAd plat-
form is more effective than uncoated viruses as the oncolytic
activity cooperates synergistically with immune system activa-
tion, hence improving the efficacy of oncolytic vaccine in a clin-
ically relevant model.
Discussion
Personalized approaches are necessary to increase the success
rate and, most importantly, to avoid the side effects associated
with powerful 22-24 but unspecific immunotherapies.25 OAds
are an attractive platform thanks to their natural immunoge-
nicity. However, the time required for the genetic and struc-
tural manipulation of these viruses represent a major limitation
for their use in personalized approaches. Therefore, we focused
on the development of a new and versatile cancer vaccine plat-
form based on OAds coated with MHC-I epitopes.
Coating the viral capsid with different polymers and materi-
als is a widely used approach to increase the infectivity of
adenoviruses 26 or to reduce the interaction with neutralizing
antibodies. The rationale behind our system is different since
we aim at improving conventional OAds by using them as
tumor killing adjuvants for the peptides used to coat their sur-
face. We first demonstrated that positive tumor epitopes bind
the negative viral capsid electrostatically and that the modified
MHC-I epitope (i.e. polyK-SIINFEKL) can be cross presented.
Interestingly, the position of the polyK chain in the peptide
sequence has an important effect on the cross presentation. In
fact, C-terminus-extended epitopes are cross presented with a
significantly lower efficiency compared with their N-terminus-
extended counterparts. These results can be explained by con-
sidering that classical and non-classical cross-presentation
mechanisms cooperate inside APCs. In fact, while the C-termi-
nus-extended epitope need to undergo the classical protea-
some-dependent cross-presentation pathway,27 the N-terminus
extended versions can take advantage of a faster alternative
pathway thanks to the presence of amino peptidases into the
phagosomes from the endoplasmic reticulum.28 Hence, our
results are consistent with other studies showing that the
sequences flanking a mature epitope affect its cross
presentation.29
We found that the infectivity of PeptiCRAd is enhanced in
cell lines with low CAR expression. Previous studies demon-
strated that the surface modification could affect the transduc-
tion efficacy of adenoviral vectors.16,30,31 In the case of
PeptiCRAd, the positive peptides bring multiple residues of
lysine that can neutralize the acidic/negative zones of the viral
Figure 7. Efficacy of PeptiCRAd in humanized mice bearing human melanomas. Humanized and non-humanized mice bearing SK-MEL-2 human melanomas were treated
with one of the following: (i) saline solution (mock), (ii) Ad5D24-GM-CSF, and (iii) MAGE-A1 PeptiCRAd. The tumor volume of the humanized mice (A) is presented as the
mean § SD (n D 3). (B) The area under the curve (AUC) relative to the size of the tumors of humanized-mice is presented. (C) The tumor volume of non-humanized mice



































capsid. Hence, with less interference, the remaining positive
areas could now favor the interaction of the capsid with the
negative cell membrane and this phenomenon becomes
important when the expression of CAR is limited.
To study the antitumor efficacy of the immunogenicity of
OAds dissociated from the oncolysis, we chose a murine model
of melanoma in which the human adenovirus serotype 5 is
unable to replicate.8 Mice treated with OVA-PeptiCRAd
showed a significantly decreased tumor growth and a larger
antigen-specific immune response compared to control. Similar
results have been reported for naked armed oncolytic viruses.8
However, in all our experiments PeptiCRAd was more effective
than naked OAds. Our data suggest that the increased efficacy
of PeptiCRAd could be due to mediated by a modulation of
APCs that could uptake the virus-epitope complex. This would
eventually cause the maturation of these cells, mainly due to
the adenoviral-danger signals, and the cross presentation of the
epitopes that are bound to the viral surface. In fact, we showed
in vivo that the proportion of DCs that were activated and
cross-presenting SIINFEKL was significantly increased in the
group of mice treated with PeptiCRAd. These results are con-
sistent with current knowledge of other vaccine systems 32 and
with a recent work showing that adjuvant-antigen complexes
are more effective than the single components because of supe-
rior targeting of APCs and, in particular, DCs.33 These results
clearly show that the immunogenicity of OAds provides antitu-
mor efficacy in absence of oncolysis, which was thought to be
the only mode of action of OAds.
Next, we studied a more relevant tumor model by using
B16-F10 tumors and targeting real tumor antigens rather
than an artificial one (i.e. chicken OVA). We found that
targeting two tumor antigens results in a broader immuno-
logical response that could explain the increased efficacy of
TRP-2-hgp100-PeptiCRAd in controlling the growth of dis-
tant untreated tumors. Targeting multiple tumor antigens is
important to limit the escape of malignant cells from
immune surveillance 34 and to manage the variability of
tumor cells.35 In fact, clinical trials have shown that patients
who responded to multiple tumor epitopes are significantly
more likely to experience stable disease or a partial
response.36 In addition, the multivalent approach is particu-
larly useful if the tumor down regulates one antigen or one
type of HLA during the therapy.37
Finally, we used a clinically relevant in vivo model: mice
bearing human melanomas and engrafted with a human
immune system. This was still not an optimal solution as the
development of graft-versus-host responses and the decrease of
functional engrafted immune cells restricted the experimental
window. For this reason, we started the treatment even if
tumors showed a smaller volume compared to other experi-
ments. Nevertheless, humanized mice represent the only model
that allows for the study of both immunological properties and
oncolytic activity of human OAds. We observed that Pepti-
CRAd could completely cure melanomas of all humanized
mice, whereas in non-humanized mice, PeptiCRAd lost its
advantage over the normal OAd. These interesting results high-
light once again the complex interaction between OAds and the
immune system. We have to consider that the immunity
attempts to clear the OAds from the host, playing in this sense
against the oncolytic virus and in favor of the tumor. Therefore,
in absence of the immune system, both viruses are effective,
whereas in presence of the immune system PeptiCRAd has a
significant advantage. In support of this, the analysis of the epi-
tope-specific CD8C T cell population revealed an increased
anti-MAGE-A1 response in mice treated with MAGE-A1 Pep-
tiCRAd compared to other control groups. In this sophisticated
model, we could appreciate the synergistic relationship between
oncolysis and the immunogenicity of oncolytic viruses. In 2006,
it was shown that cells infected by OAds undergo a particular
cell death program that is characterized by autophagy and
spreading of immunogenic signals (ATP and HMGB1 release
and calreticulin exposure).38 Along the same line of research,
recent studies attempted to exploit the immunogenic cell death
(ICD) promoted by OAds to increase the efficacy of cancer
virotherapy.8,39 We conclude that PeptiCRAd system largely
benefits from the oncolytic activity of OAds but does not relies
on it completely.
In summary, tumor-specific MHC-I-restricted epitopes can be
complexed to an OAd, and these particles can act as a novel
oncolytic vaccine platform. The possibility to target multiple
antigenic entities simultaneously, improves upon the lack of
specificity of most current immunotherapies. The clear advantage
of this approach is its versatility, as no genetic and structural
modifications of OAds are needed foster a powerful tumor-spe-
cific response and eventually re-direct it to other antigens. This
gives the PeptiCRAd platform a clear advantage upon the classic
antigen-expressing oncolytic vectors when considering highly
personalized cancer vaccine immunotherapies.
Materials and methods
Cell lines, reagents, and human samples
The human lung carcinoma cell line A549, the human CACO-2,
the human malignant melanoma cell line SK-MEL-2, the human
melanoma cell line HS294T and the mouse melanoma cell line
B16-F10 were purchased from the American Type Culture Col-
lection (ATCC; Manassas, VA, USA). The cell line B16-OVA,17
a mouse melanoma cell line expressing chicken OVA, was kindly
provided by Prof. Richard Vile (Mayo Clinic, Rochester, MN,
USA). All cell lines were cultured under appropriate conditions.
SIINFEKL (OVA257-264), polyK-SIINFEKL, SIINFEKL-
polyK, polyK-AHX-SIINFEKL, polyK-SVYDFFVWL (TRP-
2180-188), polyK-KVPRNQDWL (hgp10025-33), and polyK-
SLFRAVITK (MAGE-A196-104) peptides were purchased from
Zhejiang Ontores Biotechnologies Co. (Zhejiang, China).
The net charge of peptides was calculated by the Peptide
Property Calculator Ver. 3.1 online tool.40
The HLA genotype of the SK-MEL-2 cell line was HLA-
A03 - 26; B35 - 38; C04 - 12. Buffy coat from a healthy
donor was also obtained from the Finnish Red Cross service,
and the genotype was determined as HLA-A03 - 03; B07 -
27; C01 - 07.
OAd preparation
All OAds were generated, propagated, and characterized using
standard protocols, as previously described.41


































All viruses used in this study have been previously reported:
Ad5D24 is an adenovirus that features a 24-base-pair deletion
(D24) in the E1A gene,2 Ad5D24-CpG is an OAd bearing a
CpG-enriched genome in the E3 gene,19 and Ad5D24-GM-CSF
is an OAd expressing GM-CSF under the control of the viral
E3 promoter.5
PeptiCRAd complex formation
All PeptiCRAd complexes described in this work were prepared
by mixing oncolytic viruses and polyK-epitopes at a 1:500 ratio
according to the following protocol: (i) for each microliter of
viral preparation used, the corresponding number of micro-
grams of protein present was calculated; (ii) then, for each
microgram of viral protein, 500 mg of peptide was added; (iii)
after vortexing, the mixture was incubated at room temperature
(RT) for 15 min; and (iv) the solution was vortexed and used
for assays or animal injections. New PeptiCRAds were prepared
before each experiment using fresh reagents. All dilutions of
virus and peptides required before incubation were performed
in sterile Milli-Q water adjusted to pH 7.4. The PeptiCRAds
were then diluted with the buffer required by the assay.
Zeta potential and dynamic light scattering (DLS) analysis
Samples were prepared as described in the previous section.
Each sample was then vortexed and diluted to a final volume of
700 mL with sterile Milli-Q water adjusted to pH 7.4, after
which the sample was transferred to a polystyrene disposable
cuvette to determine the size of the complexes. Afterward, the
sample was recovered from the cuvette and transferred to a
DTS1070 disposable capillary cell (Malvern, Worcestershire,
UK) for zeta potential measurements. All measurements were
performed at 25C with a Zetasizer Nano ZS (Malvern).
Surface plasmon resonance
Measurements were performed using a multi-parametric SPR
NaviTM 220A instrument (Bionavis Ltd, Tampere, Finland).
Milli-Q water with its pH adjusted to 7.4 was used as a running
buffer. A constant flow rate of 30 mL/min was used throughout
the experiments, and temperature was set to C20C. Laser light
with a wavelength of 670 nm was used for surface plasmon
excitation.
A sensor slide with a silicon dioxide surface was activated by
3 min of plasma treatment followed by coating with APTES
((3-aminopropyl)triethoxysilane) by incubating the sensor in
50 mM APTES in toluene solution for 1 h. The sensor was then
placed into the SPR device, and the OAds were immobilized in
situ on the sensor surface of the test channel by injecting
50 mg/mL OAds in Milli-Q water (pH 7.4) for approximately
12 min, followed by a 3 min wash with 20 mM CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate).
The second flow channel was used as a reference and was
injected with Milli-Q water (pH 7.4), followed by washing with
CHAPS. The baseline was observed for at least 10 min before
sample injections. PolyK-SIINFEKL or SIINFEKL was then
injected into both flow channels of the flow cell in parallel, with
increasing concentrations.
Viability assay
MTS assay was performed according to the manufacturer’s pro-
tocol (CellTiter 96 AQueous One Solution Cell Proliferation
Assay; Promega, Nacka, Sweden). Spectrophotometric data
were acquired with Varioskan Flash Multimode Reader
(Thermo Scientific, Carlsbad, CA, USA).
Infectivity assay by ICC
Tumor cells were seeded at 2.0£105 cells per well on 24-well
plates in three or five replicates. The following day, the cells
were infected with 10 vp/cell. The plates were then centrifuged
for 90 min at 1,000 rcf at 37C, followed by incubation for
48 h. Infectivity analysis was performed using the anti-hexon
monoclonal antibody (Novus Biologicals, Littleton, CO, USA),
diluted 1:2,000. For each well, five images of non-overlapping
fields were acquired using an AMG EVOS XL microscope
(AMG group, Life Technologies). The following formula was
used to determine the infectious titer:





volume of dilution applied
:
For the infectivity comparisons, the data are presented as the
average number of spots in each field.
Cross-presentation experiment
2£106 spleenocytes in 800 mL of 10% RPMI-1640 culture
media were incubated with 200 mL of SIINFEKL, polyK-SIIN-
FEKL, SIINFEKL-polyK, or SIINFEKL-AHX-polyK peptide
dilution (0.19 mg/mL). Alternatively, 7.9£109 vp mixed with
37.5 mg of polyK-SIINFEKL (OVA-PeptiCRAd) in 200 mL of
10% RPMI-1640 was applied. The PeptiCRAd complex was
prepared as described previously. After 2 h of incubation cells
were washed and stained with either APC anti-mouse H-2Kb
bound to SIINFEKL or APC Mouse IgG1, k Isotype Ctrl (BioL-
egend, San Diego, CA, USA), and the samples were analyzed by
flow cytometry.
Animal experiments and ethical permits
All animal experiments were reviewed and approved by the
Experimental Animal Committee of the University of Helsinki
and the Provincial Government of Southern Finland. C57BL/6
mice were obtained from Scanbur (Karlslunde, Denmark), and
immunodeficient triple-knockout NOD.Cg-Prkdcscid-
IL2rgtm1Wjl/SzJ mice were obtained from Jackson Laboratories
(Bar Harbor, ME, USA).
For the efficacy experiments 3£105 B16-OVA or 1£105
B16-F10 or 2£106 SK-MEL-2 cells were injected subcutane-
ously on the flanks of mice. Three treatment injections were




































Flowcytometry analysis was performed using a BD LSR II (BD
Biosciences) or a Gallios (Beckman Coulter) flow cytometer
and FlowJo software (Tree Star, Ashland, OR, USA). Epitope-
specific T cells were studied using MHC Class I Pentamers
(ProImmune, Oxford, UK). Other antibodies used included the
following: murine and human Fc block CD16/32 (BD Phar-
Mingen); FITC anti-mouse CD8C and FITC anti-human CD8C
(ProImmune); PE/Cy7 anti-mouse CD3e, PE/Cy7 anti-mouse
CD19, FITC anti-mouse CD11c, PerCp/Cy5.5 anti-mouse
CD86, APC anti-mouse H-2Kb bound to SIINFEKL and APC
Mouse IgG1, k Isotype Ctrl (BioLegend). All staining proce-
dures were performed according to the manufacturer’s
recommendations.
Statistical analyses and correlation models
Statistical analysis was performed using GraphPad Prism 6
(GraphPad Software, Inc.., La Jolla, CA, USA). A detailed
description of the statistical methods used to analyze the data
from each experiment can be found in each figure caption. For
correlation analysis presented in Fig. 5A, a non-linear regres-
sion was used: exponential one phase decay. The model is
described by the equation
Y D Y0¡ Plateauð Þ£ e ¡K £ Xð Þ C Plateau:
Y0 is the Y value when X (time) is zero. It is expressed in the
same units as Y. Plateau is the Y value at infinite times,
expressed in the same units as Y. K is the rate constant,
expressed in reciprocal of the X axis time units. If X is in
minutes, then K is expressed in inverse minutes.
For models of virus-peptide interaction presented in Fig. S2
the following equations have been used:
One-site binding model Y D Ymax £ ½P
K C ½P
Co-operative binding model Y D Ymax ½P
a £ .Kco/a
1C ½Pa £ .Kco/a
Y D SPR response, Ymax D SPR response at saturation, [P]D
concentration of poly K-SIINFEKL, K D 1/Kco D binding con-
stant, a D Hill coefficient describing co-operativity of the inter-
action (a > 1, positive co-operativity; a < 1, negative co-
operativity).
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